An interventional study of Mindfulness based psychosexual therapy ( MBPST) in Situational Erectile Dysfunction, sponsored by Vancouver Coastal Health. Status unknown at 1 site in Canada. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-10-19.
Sponsored by Vancouver Coastal Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Erectile Dysfunction with a site in Canada — 5 open to participants now, 5 under way, none of them phase 3. Erectile Dysfunction · Canada.
Among the 29 studies in Erectile Dysfunction with a site in Canada, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2020, is one of 5 with no phase, and was the 24th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →5 of the 29 studies in Erectile Dysfunction with a site in Canada are open now. Recruiting first, the newest first:
Ryan Flannigan, MD · Sites in Canada
Ages 21–75 · Men only
University of Manitoba · Sites in Canada
Ages 30–70 · Men only · Healthy volunteers
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+ · Men only
University of Manitoba · Sites in Canada
Ages 18–70 · Men only
CancerCare Manitoba · Sites in Canada
Ages 18–80 · Men only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 19 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 120 across the 27 interventional studies, 794 across the 2 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 29 have an industry lead sponsor. The 10 most frequent:
Vancouver Coastal Health is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Vancouver Coastal Health has 1 study filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
2 of the studies in Erectile Dysfunction with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07601646Ryan Flannigan, MDA Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction | 2027-04 |
| NCT06521710Sir Mortimer B. Davis - Jewish General HospitalNerve Grafting Technique to Preserve Erectile Function in Patients Undergoing Robotic Assisted Radical Prostatectomy | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Erectile Dysfunction with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Erectile dysfunction (ED) is among the most common sexual dysfunctions experienced by men, affecting at least one third of men across the lifespan. Although pharmacological treatments are available, adherence to these treatments is poor, suggesting the need for integration of psychological interventions. This study will determine if a 6-session mindfulness-based psychosexual therapy (MBPST) group will be effective and feasible for men with situational ED. This study is adapted from a previously published 4-session MBPST protocol which was found to be beneficial for men with situational ED. Outcomes are measured using self-report questionnaires on sexual functioning/enjoyment, relationship satisfaction, and treatment acceptability.
PURPOSE The purpose of this study is to assess the feasibility and efficacy of a 6-session mindfulness-based psychosexual therapy (MBPST) treatment protocol using self-report questionnaires. The current protocol is adapted from a pre-existing 4-session mindfulness-based psychosexual therapy (MBPST) protocol from a pilot study which has already demonstrated benefits in the treatment of situational erectile dysfunction (ED). The six sessions include elements of psychoeducation, cognitive therapy, mindfulness training, and sex therapy techniques. The elements comprising the six sessions are evidence-based, as their effectiveness has been demonstrated in female samples (e.g., Brotto et al., 2012; Paterson et al., 2017), and more recently in the context of a four-session pilot in men with situational ED (H15-03172; published in Bossio et al., 2018). The rationale for an increase from a 4 to 6-session approach came from qualitative analysis of participant perspectives in the pilot study and from investigator experience.
HYPOTHESES
JUSTIFICATION Sexual dysfunction affects at least one third of men across the lifespan (Laumann, Paik, \& Rosen, 1999), and can have significant impact on quality of life and on intimate relationships (Hatzimouratidis et al., 2010). Erectile dysfunction (ED), or the inability to attain and/or maintain an erection sufficient for satisfactory sexual activity (NIH, 1993), is among the most common sexual dysfunctions experienced by men. The aetiology of ED is complex and can result from a variety of physiological (e.g., age, cardiovascular health, medication use), psychological (e.g., anxiety), and lifestyle factors (e.g., smoking status; Nicolosi, Moreira, Shirai, Tambi, \& Glasser, 2003). Situational ED refers to ED that occurs in certain contexts (e.g., with a partner), but not others (e.g., masturbation, nocturnal erections).
Although pharmacological interventions (i.e., PDE5 inhibitors) have been available to treat ED since the 1990's, adherence to these treatments is poor, with approximately 50% of men failing to re-fill their first prescription (Carvalheira, Pereira, Maroco, \& Forjaz, 2012; Hanash, 1997), despite the restoration of erections (Giannitsas, Konstantinopoulos, Patsialas, \& Perimenis, 2008). This low adherence to pharmacological treatments suggests that there are aspects of ED, beyond the rigidity of erections that are not being addressed by medications. This may be particularly true in the case of situational ED, where psychogenic factors are playing a major role (McCabe et al., 2016).
There is increasing evidence documenting the benefits of MBCT for women with sexual dysfunction (Brotto, Basson, \& Luria, 2008; Brotto et al., 2008; Brotto et al., 2012; Brotto, Seal, \& Rellini, 2012; Brotto \& Basson, 2014; Paterson, Handy, \& Brotto, 2017). Further, the investigators recently adapted a pre-existing 4-session MBPST protocol, which had already been shown to be effective in the treatment of female sexual dysfunction, to fit the needs of men with situational ED and pilot-tested it in group format (H15-03172). Our pilot data suggest significant benefits for men with situational ED (Bossio, Basson, Driscoll, Correia, \& Brotto, 2019). However, feedback from the pilot participants indicated a need for additional sessions as they had only begun to establish a regular mindfulness practice. Mindfulness-based interventions consisting of eight sessions are common and have been shown to be effective in reducing depressive symptoms (Sipe \& Eisendrath, 2012), depressive relapse (Teasdale, Segal, Williams, Ridgeway, Soulsby, \& Lau, 2000), and anxiety (Evans, Ferrando, Findler, Stowell, Smart, \& Haglin, 2008). However, the investigators were skeptical about the willingness and ability of patients to commit to eight consecutive weeks of treatment. Therefore, the current project is a pilot study intended to assess the feasibility and efficacy of a 6-session MBPST program for situational ED.
OBJECTIVES The main objective of this study is to test the feasibility and efficacy of a 6-session MBPST protocol for men with situational ED. Specifically, the investigators hope to find that men who undergo this treatment will experience improvements in primary (e.g., decreased erectile dysfunction and sexual distress), and secondary endpoints (e.g., increased relationship satisfaction and mental well-being). Further, the investigators hope to find that gains in the primary and secondary endpoints are maintained at 1- and 4-months.
RESEARCH DESIGN Participants (N=60) will take part in a 6-session MBPST group (n=6-10) for treatment of situational ED, either in-person or in an online format. Each session will be 2 hours in length and will be spaced one week apart, for a total of 12 hours of treatment time. Participants will also take part in supportive group follow-up sessions at 1- and 4-months following group completion where participants are free to share their experiences with the group, ask questions, and participate in troubleshooting. Treatment endpoints will be assessed at four time-points (pre-treatment (Time 1), immediate post-treatment (Time 2), 1-month post-treatment (Time 3), and 4-months post-treatment (Time 4)).
STATISTICAL ANALYSIS One-way repeated-measures multivariate analysis of variance (MANOVA) will be used to assess our primary hypothesis-that men will show improvements in primary (i.e., sexual functioning) endpoints following treatment-with the primary endpoint measures as the dependent variables (e.g., ED severity, sexual distress, sexual satisfaction, pleasure), time-point (pre-treatment, immediate post-treatment, 1-month post-treatment, and 4-months post-treatment) as the independent variable, and age as a covariate.
Our secondary hypotheses-that men will show improvements secondary endpoints (i.e., mindfulness-related variables, mental status, and relationship factors) following treatment-will also be examined using the same repeated-measures MANOVA strategy described above. The hypothesis that secondary endpoints act as mediators of sexual functioning following treatment will also be examined using repeated-measures ANOVAs with primary endpoint measures as the dependent variable (i.e., sexual functioning), time-point (pre-treatment, immediate post-treatment, 1-month post-treatment, and 4-months post-treatment) as the independent variable, and secondary endpoints (e.g., change in relationship satisfaction) as mediators.
Our tertiary hypothesis-that men will report using medications for ED significantly less 4-months after treatment conclusion compared with pre-treatment use-will be assessed using paired-sample t-tests comparing frequency of use and dose before treatment and 4-months after treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
This study is open to individuals who are:
Exclusion Criteria:
This study is not suitable for individuals who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients are compared to themselves before and after the treatment.
Behavioral: Mindfulness based psychosexual therapy ( MBPST)
The group treatment sessions will integrate empirically supported elements of psychoeduation, cognitive behavioural therapy, and mindfulness skills. Each of the six sessions will follow the well-defined manualized treatment protocol. The treatment is adapted from the study team's previous mindfulness-based treatment group (H15-03172), for situational ED which has been shown to be effective. Participants will be provided with handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and/or behavioural exercises between sessions. During the 2 follow-up sessions, participants will be invited to share their experience since the conclusion of group, ask questions, and participate in troubleshooting.
Also known as: MBCT ( Mindfulness based cognitive therapy )
Self-reported Erectile Functioning as measured by International Index of Erectile Function - 5
(IIEF-5; Rosen, Cappelleri, Smith, Lipsky, \& Pena, 1999); 5 item questionnaire
Time frame: Change from baseline to immediately post treatment (6 weeks)
Self-reported Erectile Functioning as measured by International Index of Erectile Function - 5
(IIEF-5; Rosen, Cappelleri, Smith, Lipsky, \& Pena, 1999); 5 item questionnaire
Time frame: Change from baseline to one month post-treatment (10 weeks)
Self-reported Erectile Functioning as measured by International Index of Erectile Function - 5
(IIEF-5; Rosen, Cappelleri, Smith, Lipsky, \& Pena, 1999); 5 item questionnaire
Time frame: Change from baseline to four months post-treatment (22 weeks)
Self-reported Sexual Distress as measured by Sexual Distress Scale-Revised
(Derogatis, Clayton, Lewis-D'Agostino, Wunderlich, \& Fu, 2008). This scale was recently validated for measuring sexual distress in men (Santos-Iglesias, Mohamed, Danko, \& Walker, 2018); 13 item rating scale
Time frame: Change from baseline to immediately post treatment (6 weeks)
Self-reported Sexual Distress as measured by Sexual Distress Scale-Revised
(Derogatis, Clayton, Lewis-D'Agostino, Wunderlich, \& Fu, 2008). This scale was recently validated for measuring sexual distress in men (Santos-Iglesias, Mohamed, Danko, \& Walker, 2018); 13 item rating scale
Time frame: Change from baseline to one month post-treatment (10 weeks)
Self-reported Sexual Distress as measured by Sexual Distress Scale-Revised
(Derogatis, Clayton, Lewis-D'Agostino, Wunderlich, \& Fu, 2008). This scale was recently validated for measuring sexual distress in men (Santos-Iglesias, Mohamed, Danko, \& Walker, 2018); 13 item rating scale
Time frame: Change from baseline to four months post-treatment (22 weeks)
Self-reported Confidence in Sexual and Erectile Competence as measured by Sexual Self-Efficacy Scale - Erectile Functioning
(Fichten, Spector, Amsel, Creti, Brender, \& Libman, 1998), which measures confidence in sexual and erectile competence; 25 item rating scale
Time frame: Change from baseline to immediately post treatment (6 weeks)
Self-reported Confidence in Sexual and Erectile Competence as measured by Sexual Self-Efficacy Scale - Erectile Functioning
(Fichten, Spector, Amsel, Creti, Brender, \& Libman, 1998), which measures confidence in sexual and erectile competence; 25 item rating scale
Time frame: Change from baseline to one month post-treatment (10 weeks)
Self-reported Confidence in Sexual and Erectile Competence as measured by Sexual Self-Efficacy Scale - Erectile Functioning
(Fichten, Spector, Amsel, Creti, Brender, \& Libman, 1998), which measures confidence in sexual and erectile competence; 25 item rating scale
Time frame: Change from baseline to four months post-treatment (22 weeks)
Self-reported Sexual Satisfaction and Pleasure as measured by International Index of Erectile Function - Overall Satisfaction Subscale.
(Rosen, Riley, Wagner, Osterloh, Kirkpatrick, \& Mishra, 1997), which measures sexual satisfaction. 2-item questionnaire
Time frame: Change from baseline to immediately post treatment (6 weeks)
Self-reported Sexual Satisfaction and Pleasure as measured by International Index of Erectile Function - Overall Satisfaction Subscale
(Rosen, Riley, Wagner, Osterloh, Kirkpatrick, \& Mishra, 1997), which measures sexual satisfaction. 2-item questionnaire
Time frame: Change from baseline to one month post-treatment (10 weeks)
Self-reported Sexual Satisfaction and Pleasure as measured by International Index of Erectile Function - Overall Satisfaction Subscale
(Rosen, Riley, Wagner, Osterloh, Kirkpatrick, \& Mishra, 1997), which measures sexual satisfaction. 2-item questionnaire
Time frame: Change from baseline to four months post-treatment (22 weeks)
Self-reported Sexual Pleasure as measured by an investigator-created Questionnaire
2-item self report questionnaire on a 5-point scale assessing physical and emotional sexual pleasure.
Time frame: Change from baseline to immediately post treatment (6 weeks)
Self-reported Sexual Pleasure as measured by an investigator-created Questionnaire
2-item self report questionnaire on a 5-point scale assessing physical and emotional sexual pleasure.
Time frame: Change from baseline to one month post-treatment (10 weeks)
Self-reported Sexual Pleasure as measured by an investigator-created Questionnaire
2-item self report questionnaire on a 5-point scale assessing physical and emotional sexual pleasure.
Time frame: Change from baseline to four months post-treatment (22 weeks)
Anxiety Symptoms as measured by Generalized Anxiety Disorder-7
(Spitzer, Kroenke, Williams, \& Lowe, 2006),7-item questionnaire
Time frame: Change from baseline to immediately post treatment (6 weeks)
Anxiety Symptoms as measured by Generalized Anxiety Disorder-7
(Spitzer, Kroenke, Williams, \& Lowe, 2006), 7-item questionnaire
Time frame: Change from baseline to one month post-treatment (10 weeks)
Anxiety Symptoms as measured by Generalized Anxiety Disorder-7
(Spitzer, Kroenke, Williams, \& Lowe, 2006), 7-item questionnaire
Time frame: Change from baseline to four months post-treatment (22 weeks)
Degree of Mindfulness as measured by the Five Facet Mindfulness Questionnaire-15
(Baer, Carmody, Hunsinger, 2012; Gu, Strauss, Crane, Barnhofer, Karl, Cavanagh, \& Kuyken, 2016),15-item questionnaire
Time frame: Change from baseline to immediately post treatment (6 weeks)
Degree of Mindfulness as measured by the Five Facet Mindfulness Questionnaire-15
(Baer, Carmody, Hunsinger, 2012; Gu, Strauss, Crane, Barnhofer, Karl, Cavanagh, \& Kuyken, 2016),15-item questionnaire
Time frame: Change from baseline to one month post-treatment (10 weeks)
Degree of Mindfulness as measured by the Five Facet Mindfulness Questionnaire-15
(Baer, Carmody, Hunsinger, 2012; Gu, Strauss, Crane, Barnhofer, Karl, Cavanagh, \& Kuyken, 2016),15-item questionnaire
Time frame: Change from baseline to four months post-treatment (22 weeks)
Non-attachment mindfulness skill as measured by Nonattachment Scale-7
(Sahdra, Ciarrochi, Parker, Marshall, \& Heaven, 2015) Non-attachment is a specific facet of mindfulness measured by this 7-item questionnaire
Time frame: Change from baseline to immediately post treatment (6 weeks)
Non-attachment mindfulness skill as measured by Nonattachment Scale-7
(Sahdra, Ciarrochi, Parker, Marshall, \& Heaven, 2015) Non-attachment is a specific facet of mindfulness measured by this 7-item questionnaire
Time frame: Change from baseline to one month post-treatment (10 weeks)
Non-attachment mindfulness skill as measured by Nonattachment Scale-7
(Sahdra, Ciarrochi, Parker, Marshall, \& Heaven, 2015) Non-attachment is a specific facet of mindfulness measured by this 7-item questionnaire
Time frame: Change from baseline to four months post-treatment (22 weeks)
Relationship satisfaction as measured by Relationship Assessment Scale
(Hendrick, 1988) 7-item questionnaire
Time frame: Change from baseline to immediately post treatment (6 weeks)
Relationship satisfaction as measured by Relationship Assessment Scale
(Hendrick, 1988) 7-item questionnaire
Time frame: Change from baseline to one month post-treatment (10 weeks)
Relationship satisfaction as measured by Relationship Assessment Scale
(Hendrick, 1988)7-item questionnaire
Time frame: Change from baseline to four months post-treatment (22 weeks)
Patient Satisfaction towards therapy group and Self-reported Impact on Quality of Sexual Life as measured by Patient Global Impression of Change Scale - Revised
(adapted from Hurst \& Bolton, 2004) This is a single self-report question on participants overall satisfaction from and impact from the treatment group
Time frame: Change from baseline to immediately post treatment (6 weeks)
Patient Satisfaction towards therapy group and Self-reported Impact on Quality of Sexual Life as measured by Patient Global Impression of Change Scale - Revised
(adapted from Hurst \& Bolton, 2004). This is a single self-report question on participants overall satisfaction from and impact from the treatment group
Time frame: Change from baseline to one month post-treatment (10 weeks)
Patient Satisfaction towards therapy group and Self-reported Impact on Quality of Sexual Life as measured by Patient Global Impression of Change Scale - Revised
(adapted from Hurst \& Bolton, 2004) This is a single self-report question on participants overall satisfaction from and impact from the treatment group
Time frame: Change from baseline to four months post-treatment (22 weeks)
PDE5 inhibitor Medication Use
As measured by self-report questions asking men about their use of PDE5 inhibitor medications to erectile functioning, and their perception of these medications usefulness
Time frame: Change from baseline to immediately post treatment (6 weeks)
PDE5 inhibitor Medication Use
As measured by self-report questions asking men about their use of PDE5 inhibitor medications to erectile functioning, and their perception of these medications usefulness
Time frame: Change from baseline to one month post-treatment (10 weeks)
PDE5 inhibitor Medication Use
As measured by self-report questions asking men about their use of PDE5 inhibitor medications to erectile functioning, and their perception of these medications usefulness
Time frame: Change from baseline to four months post-treatment (22 weeks)
Mindfulness and Sexual Activities Practice as measured by investigator-created questionnaire
Daily log of types of activities and minutes practiced
Time frame: Change from baseline to immediately post treatment (6 weeks)
Mindfulness and Sexual Activities Practice as measured by investigator-created questionnaire
Daily log of types of activities and minutes practiced
Time frame: Change from baseline to one month post-treatment (10 weeks)
Mindfulness and Sexual Activities Practice as measured by investigator-created questionnaire
Daily log of types of activities and minutes practiced
Time frame: Change from baseline to four months post-treatment (22 weeks)
Plan to share: No
Started Apr 2020 (actual). Primary completion is estimated for Dec 2024, 56 months after the start.
Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 56 months is above that.
Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vancouver Coastal Health